JP7105797B2 - 化合物及びその使用方法 - Google Patents

化合物及びその使用方法 Download PDF

Info

Publication number
JP7105797B2
JP7105797B2 JP2019548536A JP2019548536A JP7105797B2 JP 7105797 B2 JP7105797 B2 JP 7105797B2 JP 2019548536 A JP2019548536 A JP 2019548536A JP 2019548536 A JP2019548536 A JP 2019548536A JP 7105797 B2 JP7105797 B2 JP 7105797B2
Authority
JP
Japan
Prior art keywords
alkyl
carbocyclyl
optionally substituted
cyano
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019548536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535838A5 (enExample
JP2019535838A (ja
Inventor
キラン レディ，
ボテッラ， ガブリエル マルティネス
アンドリュー マーク グリフィン，
ブライアン エドワード マロン，
Original Assignee
プラクシス プレシジョン メディシンズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プラクシス プレシジョン メディシンズ， インコーポレイテッド filed Critical プラクシス プレシジョン メディシンズ， インコーポレイテッド
Publication of JP2019535838A publication Critical patent/JP2019535838A/ja
Publication of JP2019535838A5 publication Critical patent/JP2019535838A5/ja
Priority to JP2022111844A priority Critical patent/JP7495962B2/ja
Application granted granted Critical
Publication of JP7105797B2 publication Critical patent/JP7105797B2/ja
Priority to JP2024084718A priority patent/JP2024100974A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2019548536A 2016-11-28 2017-11-28 化合物及びその使用方法 Active JP7105797B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022111844A JP7495962B2 (ja) 2016-11-28 2022-07-12 化合物及びその使用方法
JP2024084718A JP2024100974A (ja) 2016-11-28 2024-05-24 化合物及びその使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662427044P 2016-11-28 2016-11-28
US62/427,044 2016-11-28
US201762458306P 2017-02-13 2017-02-13
US62/458,306 2017-02-13
US201762552073P 2017-08-30 2017-08-30
US62/552,073 2017-08-30
PCT/US2017/063533 WO2018098499A1 (en) 2016-11-28 2017-11-28 Compounds and their methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022111844A Division JP7495962B2 (ja) 2016-11-28 2022-07-12 化合物及びその使用方法

Publications (3)

Publication Number Publication Date
JP2019535838A JP2019535838A (ja) 2019-12-12
JP2019535838A5 JP2019535838A5 (enExample) 2021-01-07
JP7105797B2 true JP7105797B2 (ja) 2022-07-25

Family

ID=62195384

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019548536A Active JP7105797B2 (ja) 2016-11-28 2017-11-28 化合物及びその使用方法
JP2022111844A Active JP7495962B2 (ja) 2016-11-28 2022-07-12 化合物及びその使用方法
JP2024084718A Pending JP2024100974A (ja) 2016-11-28 2024-05-24 化合物及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022111844A Active JP7495962B2 (ja) 2016-11-28 2022-07-12 化合物及びその使用方法
JP2024084718A Pending JP2024100974A (ja) 2016-11-28 2024-05-24 化合物及びその使用方法

Country Status (13)

Country Link
US (3) US11629146B2 (enExample)
EP (2) EP4397308A3 (enExample)
JP (3) JP7105797B2 (enExample)
CN (2) CN116763791A (enExample)
AU (3) AU2017364901A1 (enExample)
BR (1) BR112019010880A2 (enExample)
DK (1) DK3548033T3 (enExample)
ES (1) ES2992063T3 (enExample)
FI (1) FI3548033T3 (enExample)
HU (1) HUE068842T2 (enExample)
PL (1) PL3548033T3 (enExample)
PT (1) PT3548033T (enExample)
WO (1) WO2018098499A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021525800A (ja) * 2018-05-30 2021-09-27 プラクシス プレシジョン メディシンズ， インコーポレイテッド イオンチャネルモジュレーター

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018098499A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11261188B2 (en) 2016-11-28 2022-03-01 Praxis Precision Medicines, Inc. Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11731966B2 (en) 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
EP3840733A4 (en) 2018-08-20 2022-07-20 Rogcon, Inc. ANTISENSE OLIGONUCLEOTIDES DIRECTED TO SCN2A FOR THE TREATMENT OF SCN1A ENCEPHALOPATHIES
EA202092908A1 (ru) * 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
WO2021039961A1 (ja) * 2019-08-30 2021-03-04 大日本住友製薬株式会社 縮環ピラゾール誘導体
BR112022010186A2 (pt) * 2019-11-26 2022-08-09 Praxis Prec Medicines Inc Moduladores de canal iônico
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
JP2023504038A (ja) * 2019-11-27 2023-02-01 プラクシス プレシジョン メディシンズ， インコーポレイテッド イオンチャネルモジュレーターの製剤ならびにイオンチャネルモジュレーターの調製および使用の方法
JP2021195367A (ja) * 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物
KR20240088848A (ko) * 2021-09-13 2024-06-20 베링거잉겔하임베트메디카게엠베하 사이클로프로필-(헤테로)아릴-치환된 에틸설포닐-피리딘 유도체
AU2023260468A1 (en) * 2022-04-26 2024-11-28 Praxis Precision Medicines, Inc. Treatment of neurological disorders
CN120641418A (zh) * 2022-10-07 2025-09-12 腾维治疗公司 化合物、组合物和方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110021521A1 (en) 2009-07-27 2011-01-27 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4230705A (en) * 1976-09-22 1980-10-28 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety
CA1080712A (en) * 1976-09-22 1980-07-01 Jay D. Albright Hypotensive agents
US4112095A (en) * 1976-10-07 1978-09-05 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents
US4242515A (en) 1979-03-28 1980-12-30 American Cyanamid Company Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
GB9507348D0 (en) * 1995-04-08 1995-05-31 Knoll Ag Therapeutic agents
JP2004532792A (ja) 2000-07-14 2004-10-28 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー 神経障害を治療するためのイミダゾ［１，２−ａ］ピラジン
NZ544162A (en) * 2003-05-29 2008-09-26 Shire Llc Abuse resistant amphetamine compounds
CA2556404A1 (en) * 2004-02-18 2005-08-25 Banyu Pharmaceutical Co., Ltd. Nitrogenous fused heteroaromatic ring derivative
WO2006061428A2 (en) * 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
US20100088778A1 (en) 2005-06-16 2010-04-08 John Charles Mulley Methods of Treatment, and Diagnosis of Epilepsy by Detecting Mutations in the SCN1A Gene
ES2612377T3 (es) 2005-12-21 2017-05-16 Janssen Pharmaceutica N.V. Triazolopiridazinas como moduladores de tirosina cinasas
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
FR2915198B1 (fr) 2007-04-18 2009-12-18 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
AU2009212254A1 (en) 2008-02-06 2009-08-13 Cv Therapeutics, Inc. Use of Ranolazine for treating pain
WO2010053757A1 (en) 2008-10-29 2010-05-14 Gilead Palo Alto, Inc. 2 -oxoquinoxalin blockers of the late sodium channel
US20100113514A1 (en) 2008-10-30 2010-05-06 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
WO2010056865A1 (en) 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Quinoline derivatives as ion channel modulators
BR122013027950A2 (pt) 2008-12-24 2019-12-10 BIAL PORTELA & Cª S A compostos farmacêuticos
JP5340798B2 (ja) 2009-05-07 2013-11-13 タイガースポリマー株式会社 地中埋設管の製造方法
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
FR2953520B1 (fr) 2009-12-04 2011-11-25 Sanofi Aventis Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
BR112012033402A2 (pt) 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
WO2012065297A1 (en) 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
EP2704573A4 (en) 2011-05-03 2014-10-15 Merck Sharp & Dohme AMINOMETHYL biaryl BENZOTRIAZOL DERIVATIVES
WO2012154760A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
NO3175985T3 (enExample) 2011-07-01 2018-04-28
EP2758053A1 (en) 2011-09-21 2014-07-30 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
BR112014006924B1 (pt) 2011-09-27 2020-10-06 Genfit Derivados de triazolopiridazinas 6-substituídas como agonistas de rev-erb
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
TWI574962B (zh) * 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
WO2014100764A2 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Methods of inhibiting prmt5
WO2014179492A1 (en) 2013-05-01 2014-11-06 Gilead Sciences, Inc. Combination therapy for the treatment of arrhythmias or heart failure
HRP20200854T1 (hr) 2013-06-21 2020-08-21 Zenith Epigenetics Ltd. Novi biciklički inhibitori bromodomene
WO2015026849A1 (en) 2013-08-19 2015-02-26 The Regents Of The University Of California Compounds and methods for treating an epileptic disorder
GB201321740D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
EA029415B1 (ru) 2013-12-19 2018-03-30 Джилид Сайэнс, Инк. Производные 2-оксо-3,4-дигидро-2н-бензо[e][1,3]оксазина
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
AU2015271719A1 (en) * 2014-06-04 2016-12-01 Rugen Holdings (Cayman) Limited Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists
ES2912073T3 (es) 2014-06-20 2022-05-24 Mitsubishi Chem Corp Policarbonatodiol, método para producir el mismo, y poliuretano producido usando el mismo
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
PE20161476A1 (es) 2014-06-26 2017-01-07 Hoffmann La Roche Derivados de indolin-2-ona o pirrolo-piridin-2-ona
JP2017001991A (ja) 2015-06-11 2017-01-05 大日本住友製薬株式会社 新規ベンズオキサゾロン化合物
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
US20210188839A1 (en) 2016-11-28 2021-06-24 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11261188B2 (en) 2016-11-28 2022-03-01 Praxis Precision Medicines, Inc. Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
WO2018098499A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11731966B2 (en) 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
KR102809796B1 (ko) 2018-05-30 2025-05-20 프락시스 프리시젼 메디신즈, 인크. 이온 채널 조절인자
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
BR112022010186A2 (pt) 2019-11-26 2022-08-09 Praxis Prec Medicines Inc Moduladores de canal iônico
JP2023504038A (ja) 2019-11-27 2023-02-01 プラクシス プレシジョン メディシンズ， インコーポレイテッド イオンチャネルモジュレーターの製剤ならびにイオンチャネルモジュレーターの調製および使用の方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110021521A1 (en) 2009-07-27 2011-01-27 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
European Journal of Medicinal Chemistry，2010年，45，pp.1746-1752
FILE REGISTRY ON STN, RN 1347643-11-1, Entered STN: 02 Dec 2011
J. Med. Chem.，1981年，24，pp.592-600

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021525800A (ja) * 2018-05-30 2021-09-27 プラクシス プレシジョン メディシンズ， インコーポレイテッド イオンチャネルモジュレーター
JP2023144130A (ja) * 2018-05-30 2023-10-06 プラクシス プレシジョン メディシンズ， インコーポレイテッド イオンチャネルモジュレーター
JP7359847B2 (ja) 2018-05-30 2023-10-11 プラクシス プレシジョン メディシンズ， インコーポレイテッド イオンチャネルモジュレーター
JP7603118B2 (ja) 2018-05-30 2024-12-19 プラクシス プレシジョン メディシンズ， インコーポレイテッド イオンチャネルモジュレーター

Also Published As

Publication number Publication date
EP4397308A2 (en) 2024-07-10
AU2023282271A1 (en) 2024-01-18
AU2017364901A1 (en) 2019-06-13
BR112019010880A2 (pt) 2019-10-01
ES2992063T3 (es) 2024-12-09
US11629146B2 (en) 2023-04-18
CN116763791A (zh) 2023-09-19
CA3045121A1 (en) 2018-05-31
JP2022141773A (ja) 2022-09-29
EP4397308A3 (en) 2024-08-21
AU2025237912A1 (en) 2025-10-16
PT3548033T (pt) 2024-08-09
JP7495962B2 (ja) 2024-06-05
WO2018098499A1 (en) 2018-05-31
EP3548033A1 (en) 2019-10-09
DK3548033T3 (da) 2024-07-15
EP3548033A4 (en) 2020-09-09
US20250163068A1 (en) 2025-05-22
US20210188852A1 (en) 2021-06-24
PL3548033T3 (pl) 2025-06-02
US20230322790A1 (en) 2023-10-12
HUE068842T2 (hu) 2025-01-28
EP3548033B1 (en) 2024-04-10
CN110337295B (zh) 2023-06-09
JP2019535838A (ja) 2019-12-12
FI3548033T3 (fi) 2024-07-10
JP2024100974A (ja) 2024-07-26
CN110337295A (zh) 2019-10-15

Similar Documents

Publication Publication Date Title
JP7495962B2 (ja) 化合物及びその使用方法
JP7603118B2 (ja) イオンチャネルモジュレーター
JP7576539B2 (ja) イオンチャネルモジュレーター
US11731966B2 (en) Compounds and their methods of use
US11261188B2 (en) Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
US11918571B2 (en) Compounds and their methods of use
US11492345B2 (en) Compounds and their methods of use
WO2018098500A1 (en) Compounds and their methods of use
JP2023503343A (ja) イオンチャネルモジュレーター
CA3045121C (en) Compounds and their methods of use
HK40013290B (en) Compounds and their methods of use
HK40013290A (en) Compounds and their methods of use
HK40014215A (en) Compounds and their methods of use
EA046723B1 (ru) Соединения и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220609

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220712

R150 Certificate of patent or registration of utility model

Ref document number: 7105797

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250